128 related articles for article (PubMed ID: 36620558)
1. Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET.
Tatsumi M; Soeda F; Naka S; Kurimoto K; Ooe K; Fukui H; Katayama D; Watabe T; Kato H; Tomiyama N
Front Oncol; 2022; 12():1026608. PubMed ID: 36620558
[TBL] [Abstract][Full Text] [Related]
2. Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [
Beshr R; Isohashi K; Watabe T; Naka S; Horitsugi G; Romanov V; Kato H; Miyatake SI; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2018 Dec; 32(10):702-708. PubMed ID: 30194665
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FBPA as a tumor specific tracer of L-type amino acid transporter 1 (LAT1): PET evaluation in tumor and inflammation compared to (18)F-FDG and (11)C-methionine.
Watabe T; Hatazawa J
Hell J Nucl Med; 2015; 18 Suppl 1():149. PubMed ID: 26665232
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the threshold SUV for diagnosis of malignancy using
Isohashi K; Kanai Y; Aihara T; Hu N; Fukushima K; Baba I; Hirokawa F; Kakino R; Komori T; Nihei K; Hatazawa J; Ono K
Eur J Hybrid Imaging; 2022 Dec; 6(1):35. PubMed ID: 36464732
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6.
Watabe T; Ikeda H; Nagamori S; Wiriyasermkul P; Tanaka Y; Naka S; Kanai Y; Hagiwara K; Aoki M; Shimosegawa E; Kanai Y; Hatazawa J
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):321-331. PubMed ID: 27550420
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
8. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
[TBL] [Abstract][Full Text] [Related]
9. Can physiologic colonic [
Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
[TBL] [Abstract][Full Text] [Related]
10. 4-Borono-2-
Ishiwata K
Ann Nucl Med; 2019 Apr; 33(4):223-236. PubMed ID: 30820862
[TBL] [Abstract][Full Text] [Related]
11. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
[TBL] [Abstract][Full Text] [Related]
14. Influence on [
Tomita M; Suzuki M; Kono Y; Nakajima K; Matsuda T; Kuge Y; Ogawa M
EJNMMI Res; 2020 Mar; 10(1):24. PubMed ID: 32189078
[TBL] [Abstract][Full Text] [Related]
15. Comparison of
Igaki H; Nakamura S; Kurihara H; Abe Y; Nishioka S; Fujii R; Nakamura M; Nakayama Y; Morita T; Okamoto H; Imahori Y; Itami J
Appl Radiat Isot; 2020 Mar; 157():109019. PubMed ID: 31889678
[TBL] [Abstract][Full Text] [Related]
16. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
17. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study With Immunohistological Comparison.
Watabe T; Ose N; Naka S; Fukui E; Kimura T; Kanou T; Funaki S; Sasaki H; Kamiya T; Kurimoto K; Isohashi K; Tatsumi M; Shimosegawa E; Kato H; Ohgaki R; Kanai Y; Shintani Y
Clin Nucl Med; 2023 Oct; 48(10):853-860. PubMed ID: 37682600
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of D-isomer of
Hirai N; Watabe T; Nagamori S; Wiriyasermkul P; Tanaka Y; Romanov V; Naka S; Kanai Y; Liu Y; Tani N; Sakai T; Tatsumi M; Shimosegawa E; Kanai Y; Hatazawa J
Asia Ocean J Nucl Med Biol; 2020; 8(2):102-108. PubMed ID: 32714997
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
